Ignite Creation Date:
2024-05-05 @ 6:38 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00512876
Status:
COMPLETED
Last Update Posted:
2013-07-22
First Post:
2007-08-06
Brief Title:
Effectiveness and Safety of Topical Bevacizumab Avastin for Treatment of Corneal Neovascularization
Sponsor:
Walter Reed Army Medical Center
Organization:
Walter Reed Army Medical Center
Study Overview
Official Title:
Effectiveness and Safety of Topical Bevacizumab Avastin for Treatment of Corneal Neovascularization
Status:
COMPLETED
Status Verified Date:
2013-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Purpose To determine the efficacy and safety of one commonly used VEGF inhibitor bevacizumab Avastin Genentech as a topical agent for the treatment of corneal neovascularization
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None